Advanced hepatocellular carcinoma with lymph node metastases showing epithelial to mesenchymal transition effectively treated with systemic chemotherapy: Report of a case

Hepatology Research

Volumn 43, Issue 12, 2013, Pages 1368-1373

  Sadamori, Hiroshi ^a   Yagi, Takahito ^a   Shigeyasu, Kunitoshi ^a   Umeda, Yuzo ^a   Sugihara, Masahiro ^a   Yokomichi, Naosuke ^a   Ohara, Toshiaki ^a   Nishida, Naoshi ^b   Nagasaka, Takeshi ^a   Goel, Ajay ^c   Fujiwara, Toshiyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Epithelial to mesenchymal transition; Hepatocellular carcinoma; Liver resection; Lymph node metastases

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CISPLATIN; DECARBOXYPROTHROMBIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HEMOPOIETIC GROWTH FACTOR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; NERVE CELL ADHESION MOLECULE; SERUM ALBUMIN; UVOMORULIN; VIMENTIN; VIRUS DNA;

ADULT; ADVANCED CANCER; ALPHA FETOPROTEIN BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHILD PUGH SCORE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; EPITHELIAL MESENCHYMAL TRANSITION; HEPATITIS B; HUMAN; IMMUNOHISTOCHEMISTRY; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER RESECTION; LOBECTOMY; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROPER HEPATIC ARTERY; PROTEIN EXPRESSION; PROTHROMBIN TIME; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TUMOR REGRESSION;

EID: 84891006369     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12080     Document Type: Article

References (18)

1. Xiaohong S, Huikai L, Feng W, Ti Z, Yunlong C, Qiang L. Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. World J Surg 2010; 34: 1028-1033.
2. Ercolani G, Grazi GL, Ravaioli M etal. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg 2004; 239: 202-209.
3. Abe T, Furuse J, Yoshino M etal. Clinical characteristics of hepatocellular carcinoma with an extensive lymph node metastasis at diagnosis. Am J Clin Oncol 2002; 25: 318-323.
4. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-374.
5. Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008; 47: 1557-1566.
6. Lee TK, Poon RT, Yuen AP etal. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006; 12: 5369-5376.
7. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
8. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
9. Fuchs BC, Fujii T, Dorfman JD etal. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008; 68: 2391-2399.
10. van Zijl F, Mall S, Machat G etal. A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther 2011; 10: 850-860.
11. Nakamura M, Nagano H, Marubashi S etal. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008; 112: 1765-1771.
12. Uka K, Aikata H, Mori N etal. Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology 2008; 75: 8-16.
13. Uchino K, Obi S, Tateishi R etal. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol 2012; 47: 1152-1159.
14. Ishikawa T, Imai M, Kamimura H etal. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol 2007; 13: 5465-5470.
15. Yuan JN, Chao Y, Lee WP etal. Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Med Oncol 2008; 25: 201-206.
16. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
17. Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS. AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res 2010; 70: 7360-7364.
18. Hu L, Lau SH, Tzang CH etal. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 2004; 23: 298-302.